In Brief: Pall Corporation
This article was originally published in The Gray Sheet
Pall Corporation: Enters an agreement in principle to acquire for $41 mil. the assets of Bayer Corporation's Medical Plastics business, which manufacturers disposable plastic products and preservative solutions for blood collection and storage. The deal builds on an existing collaboration between the firms. Bayer's blood collection sets have incorporated Pall's leukocyte depletion filters since 1990, and Pall is the sales representative for European and U.S. sales of Bayer products using its filters....
You may also be interested in...
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.